George Mosialos
Thessaloniki, ESYE12 54124, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025
The deubiquitinase activity of CYLD is required for B cell differentiation.
Journal: Cell death & disease
Published: August 07, 2025
Phenotypic analysis of mice with inactivation of the deubiquitinating enzyme CYLD in adipose tissue.
Phenotypic analysis of mice with inactivation of the deubiquitinating enzyme CYLD in adipose tissue.
Journal: Cell and tissue research
Published: April 03, 2025
Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
Journal: Anticancer research
Published: February 25, 2024
Cyld restrains the hyperactivation of synovial fibroblasts in inflammatory arthritis by regulating the TAK1/IKK2 signaling axis.
Journal: Cell death & disease
Published: February 07, 2024
Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency.
Journal: Cancers
Published: October 01, 2023
The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.
Journal: Cancers
Published: May 27, 2020
HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.
Journal: OncoTargets and therapy
Published: February 17, 2020
Deubiquitination of NLRP6 inflammasome by Cyld critically regulates intestinal inflammation.
Journal: Nature immunology
Published: August 02, 2019
Last Updated: 09/26/2026